Topotecan for the treatment of relapsed small-cell lung cancer

NICE technology appraisals [TA184] Published date:

Oral topotecan is recommended as a possible treatment for people with relapsed small-cell lung cancer if:

  • re-treatment with the previous treatment is not considered appropriate and
  • there is a medical reason why they cannot take the combination of cyclophosphamide, doxorubicin and vincristine (CAV).

Intravenous topotecan is not recommended for people with relapsed small-cell lung cancer.

Healthcare professionals should not stop prescribing topotecan for people with relapsed small-cell lung cancer who were already taking it when the guidance was issued. These people should be able to carry on taking topotecan until they and their specialist decide that it is the right time to stop treatment.

Get involved